Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Vertex Pharmaceuticals
Deal Size : $466.0 million
Deal Type : Termination
Vertex Axes Verve Gene Editing Pact Amid Shift in R&D Priorities
Details : Through the termination, Verve has now regained all rights to develop nonclinical-stage program, which is being evaluated for the treatment of Liver Disease.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $60.0 million
February 27, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Vertex Pharmaceuticals
Deal Size : $466.0 million
Deal Type : Termination
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $470.0 million
Deal Type : Collaboration
Regeneron and Mammoth Biosciences Partner to Develop CRISPR Gene Editing Therapies
Details : Under the collaboration, Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s delivery technologies are set to advance in vivo study in multiple tissue and cell types.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $100.0 million
April 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $470.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1,035.0 million
Deal Type : Partnership
Ochre Bio Partners with Boehringer Ingelheim for Advanced Liver Disease Treatments
Details : The partnership focuses on discovering first-in-class regenerative treatments for chronic liver diseases like metabolic dysfunction-associated cirrhosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $35.0 million
April 22, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1,035.0 million
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Variant Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Evotec And Variant Bio Form Partnership To Discover And Develop Treatments For Fibrosis
Details : The strategic partnership leverages Variant Bio's cutting-edge genomic discovery capabilities and VB-Inference platform to identify a best-in-class small molecule for diseases caused by fibrosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Variant Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Andreessen Horowitz
Deal Size : $118.0 million
Deal Type : Series B Financing
Details : The Company intends to use the net proceeds to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Andreessen Horowitz
Deal Size : $118.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Xiamen Amoytop Biotech Co., Ltd
Deal Size : $109.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Aligos and Amoytop will use Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Xiamen Amoytop Biotech Co., Ltd
Deal Size : $109.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Merck & Co
Deal Size : $1,380.0 million
Deal Type : Expanded Collaboration
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
Details : Under the original agreement, Merck and Aligos committed to applying Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a certain undisclosed non-alcoholic steatohepatitis (NASH) ta...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Merck & Co
Deal Size : $1,380.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Vertex Pharmaceuticals
Deal Size : $466.0 million
Deal Type : Collaboration
Details : Under the terms of the collaboration, Verve will advance the discovery, research and certain preclinical development of a novel in vivo gene editing program for the target of interest, with all program costs funded by Vertex.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $60.0 million
July 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Vertex Pharmaceuticals
Deal Size : $466.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Novartis Announces Collaboration with Alnylam to Explore Targeted Therapy to Restore Liver Function
Details : Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Temasek Life Sciences Laboratory
Deal Size : $215.0 million
Deal Type : Series B Financing
Details : Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while continuing to invest in its novel discovery engine to develop the next generation of ge...
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
September 11, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Temasek Life Sciences Laboratory
Deal Size : $215.0 million
Deal Type : Series B Financing